-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent times, domestic pharmaceutical companies have been trading frequently in terms of new drugs
.
According to incomplete statistics, in November 2021, Chinese biomedical companies have concluded at least 12 new drug transactions
.
Among them, the new drug authorization cooperation between Chinese companies is very active, such as Jichuan Pharmaceutical and Tianjing Biological, Hengrui Pharmaceuticals and CStone Pharmaceuticals, Geli and Corning Jereh, CSPC and Connoa Biologicals, etc.
A new drug deal was reached this month
.
For example, on November 11, Jichuan Pharmaceutical issued an announcement, announcing that it had reached a strategic cooperation in product development, production and commercialization with Tianjing Bio on long-acting recombinant human growth hormone (Yitan)
.
Jichuan Pharmaceutical will pay an advance payment of 224 million yuan to Tianjing Bio, and follow-up payments of no more than 1.
792 billion yuan in milestone payments, with a total payment of 2.
016 billion yuan
.
On November 21, Hengrui Pharmaceuticals announced that it has reached a strategic cooperation agreement of approximately RMB 1.
3 billion with CStone Pharmaceuticals.
It will introduce CS1002 anti-CTLA-4 monoclonal antibody from CStone Pharmaceuticals.
Hengrui Pharmaceuticals will obtain CS1002 in Greater China.
Exclusive rights for regional research and development, registration, production and commercialization
.
In the future, both parties will use their respective strengths in innovative R&D and commercial marketing to accelerate the subsequent development and commercialization of the tumor immune framework product CS1002
.
On November 22, Connoa announced that it has exclusively authorized the development of an innovative drug CM326 (a recombinant humanized monoclonal antibody against TSLP) with CSPC in moderate to severe asthma and chronic obstructive pulmonary disease (COPD) and other respiratory diseases And commercialization formally signed an agreement
.
According to the agreement, Connoa will grant an exclusive license to CSPC CM326 to develop and commercialize the product in China (excluding Hong Kong, Macau and Taiwan) and become the holder of a marketing license
.
Connoa will receive an advance payment of RMB 100 million from CSPC, a development milestone payment of up to RMB 100 million, as well as a sales milestone payment and a sales commission
.
In addition to the frequent transactions of domestic companies, Zai Lab, Enhua Pharmaceuticals, and Xiweida Biotech also "license-in" innovative therapies from overseas this month; in addition, Luye Pharmaceuticals and Livzon Group have achieved the licensing of innovative drugs.
-out" to overseas companies
.
Take Livzon Group as an example.
Its holding subsidiary Livzonumab has reached a research cooperation and licensing agreement with Bright Peak Therapeutics (hereinafter referred to as BPTx) in the United States
.
According to the agreement, Livzumab will license the recombinant humanized anti-PD-1 monoclonal antibody (LZM009) for injection with independent intellectual property rights to BPTx for a paid and non-exclusive license for the development of new PD-1 targeted immune cytokines (PD- 1 ICs), while authorizing LZM009 to BPTx for the development and commercialization of PD-1 ICs drugs in regions other than Greater China
.
In addition to the above companies, since this year, the cooperation "marriage" between pharmaceutical companies has been very frequent.
For example, the cooperation between local pharmaceutical companies and innovative pharmaceutical companies, innovative pharmaceutical companies and multinational pharmaceutical companies, and large and small companies are increasing.
Much
.
The analysis believes that this is mainly due to the fact that China is actively promoting the development of innovative drugs, and at the same time, it has always insisted that innovative drugs need to adhere to the clinical value orientation
.
It is worth noting that from the current point of view, the increasing frequency of new drug transactions has fully demonstrated that the innovative drugs of Chinese pharmaceutical companies are gaining more recognition
.
In this context, the industry expects that in the future, companies will better complement each other's advantages, and at the same time, they can share risks and flexibly mobilize the resources of both parties to further promote the research and development of innovative drugs, accelerate the commercialization process, and benefit more patients
.
.
According to incomplete statistics, in November 2021, Chinese biomedical companies have concluded at least 12 new drug transactions
.
Among them, the new drug authorization cooperation between Chinese companies is very active, such as Jichuan Pharmaceutical and Tianjing Biological, Hengrui Pharmaceuticals and CStone Pharmaceuticals, Geli and Corning Jereh, CSPC and Connoa Biologicals, etc.
A new drug deal was reached this month
.
For example, on November 11, Jichuan Pharmaceutical issued an announcement, announcing that it had reached a strategic cooperation in product development, production and commercialization with Tianjing Bio on long-acting recombinant human growth hormone (Yitan)
.
Jichuan Pharmaceutical will pay an advance payment of 224 million yuan to Tianjing Bio, and follow-up payments of no more than 1.
792 billion yuan in milestone payments, with a total payment of 2.
016 billion yuan
.
On November 21, Hengrui Pharmaceuticals announced that it has reached a strategic cooperation agreement of approximately RMB 1.
3 billion with CStone Pharmaceuticals.
It will introduce CS1002 anti-CTLA-4 monoclonal antibody from CStone Pharmaceuticals.
Hengrui Pharmaceuticals will obtain CS1002 in Greater China.
Exclusive rights for regional research and development, registration, production and commercialization
.
In the future, both parties will use their respective strengths in innovative R&D and commercial marketing to accelerate the subsequent development and commercialization of the tumor immune framework product CS1002
.
On November 22, Connoa announced that it has exclusively authorized the development of an innovative drug CM326 (a recombinant humanized monoclonal antibody against TSLP) with CSPC in moderate to severe asthma and chronic obstructive pulmonary disease (COPD) and other respiratory diseases And commercialization formally signed an agreement
.
According to the agreement, Connoa will grant an exclusive license to CSPC CM326 to develop and commercialize the product in China (excluding Hong Kong, Macau and Taiwan) and become the holder of a marketing license
.
Connoa will receive an advance payment of RMB 100 million from CSPC, a development milestone payment of up to RMB 100 million, as well as a sales milestone payment and a sales commission
.
In addition to the frequent transactions of domestic companies, Zai Lab, Enhua Pharmaceuticals, and Xiweida Biotech also "license-in" innovative therapies from overseas this month; in addition, Luye Pharmaceuticals and Livzon Group have achieved the licensing of innovative drugs.
-out" to overseas companies
.
Take Livzon Group as an example.
Its holding subsidiary Livzonumab has reached a research cooperation and licensing agreement with Bright Peak Therapeutics (hereinafter referred to as BPTx) in the United States
.
According to the agreement, Livzumab will license the recombinant humanized anti-PD-1 monoclonal antibody (LZM009) for injection with independent intellectual property rights to BPTx for a paid and non-exclusive license for the development of new PD-1 targeted immune cytokines (PD- 1 ICs), while authorizing LZM009 to BPTx for the development and commercialization of PD-1 ICs drugs in regions other than Greater China
.
In addition to the above companies, since this year, the cooperation "marriage" between pharmaceutical companies has been very frequent.
For example, the cooperation between local pharmaceutical companies and innovative pharmaceutical companies, innovative pharmaceutical companies and multinational pharmaceutical companies, and large and small companies are increasing.
Much
.
The analysis believes that this is mainly due to the fact that China is actively promoting the development of innovative drugs, and at the same time, it has always insisted that innovative drugs need to adhere to the clinical value orientation
.
It is worth noting that from the current point of view, the increasing frequency of new drug transactions has fully demonstrated that the innovative drugs of Chinese pharmaceutical companies are gaining more recognition
.
In this context, the industry expects that in the future, companies will better complement each other's advantages, and at the same time, they can share risks and flexibly mobilize the resources of both parties to further promote the research and development of innovative drugs, accelerate the commercialization process, and benefit more patients
.
